Immunotherapy combo tested to fight spreading colon cancer
NCT ID NCT02437071
Summary
This study tested whether adding the immunotherapy drug pembrolizumab to standard radiation or tumor ablation could help control metastatic colorectal cancer. It involved 34 patients whose cancer had spread and who had already tried at least two standard treatments. Researchers wanted to see if this combination could trigger the immune system to attack cancer tumors throughout the body, not just those directly treated with radiation or ablation.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC COLORECTAL CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Memorial Sloan Kettering Cancer Center
New York, New York, 10065, United States
Conditions
Explore the condition pages connected to this study.